---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-103532"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T20:18:39.468940+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MannKind Q2 revenue $76.5M (+6% YoY); Afrezza sBLA for pediatric population submitted

## Summary
- Total revenues $76.5M, up 6% YoY; net income $0.7M versus net loss $2.0M in Q2 2024.
- Afrezza sales $18.3M (+13% YoY); royalties from Tyvaso DPI $31.2M (+22%).
- Non-GAAP net income $13.9M ($0.05/share) vs $14.3M ($0.05) in Q2 2024.
- Submitted sBLA for Afrezza in pediatric patients (ages 4-17); FDA decision expected early Q4 2025.
- ICoN-1 trial of MNKD-101 enrollment ahead of schedule; interim target of 100 patients expected early Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-103532
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000095017025103532/0000950170-25-103532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000095017025103532/mnkd-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-103532
- JSON: https://secwatch.observer/filing/0000950170-25-103532.json
- Plain text: https://secwatch.observer/filing/0000950170-25-103532.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.